NeuroMab™ Anti-ApoC3 BBB Shuttle Antibody(NRZP-1022-ZP3507)

Figure 1 shows that the 5E5VH5_VL8 antibody attenuates the ability of ApoC3 to inhibit the uptake of very low density lipoprotein (VLDL) by HepG2 cells.

Figure 2 shows the pharmacokinetics and pharmacodynamics of two anti-ApoC3 antibodies, 5E5 and 5E5VH5_VL8, and an anti-egg lysosomal human IgG1 antibody (HyHe15) in the AAV8-human ApoC3 mouse model.

Test antibodies were administered intravenously to mice expressing transgenic human ApoC3. Measure human IgG1 serum levels at various times after injection and plot absolute or relative levels compared to time 0.

Figure 3 shows the pharmacokinetics and pharmacodynamics of two anti-ApoC3 antibodies 5E5 and 5E5VH5_VL8 and an anti-egg lysosomal human IgG1 antibody (HyHe15) in the AAV8-human ApoC3 mouse model.

Test antibodies were administered intravenously to mice expressing transgenic human ApoC3. Serum levels of human ApoC3 were measured at various times after injection and the absolute or relative levels compared to time 0 were plotted.

Figure 4 shows the pharmacokinetics and pharmacodynamics of two anti-ApoC3 antibodies, 5E5 and 5E5VH5_VL8, and an anti-egg lysosomal human IgG1 antibody (HyHe15) in the AAV8-human ApoC3 mouse model.

Test antibodies were administered intravenously to mice expressing transgenic human ApoC3. Serum levels of ApoB in mice were measured at different times after injection and plotted as absolute or relative levels compared to time 0.

Figure 5 shows that 5E5VH5_VL8 reduces fasting triglyceride levels and circulating postprandial triglyceride levels in the AAV8-human ApoC3 mouse model (n=6 per treatment group).

The plasma triglyceride levels in mice treated with 5E5VH5_VL8 or the HyHe15 antibody before and after fasting overnight.

Figure 6 shows that 5E5VH5_VL8 reduces fasting triglyceride levels and circulating postprandial triglyceride levels in the AAV8-human ApoC3 mouse model (n=6 per treatment group).

The plasma triglyceride levels in these mice after an olive oil challenge.

Figure 7 shows that 5E5VH5_VL8 reduces fasting triglyceride levels and circulating postprandial triglyceride levels in the AAV8-human ApoC3 mouse model (n=6 per treatment group).

The calculated area under the curve values are plotted.

Figure 8 shows that 5E5VH5_VL8 reduces fasting and circulating postprandial triglyceride levels in the AAV8-human ApoC3 mouse model (n=6 per treatment group).

ApoC3 levels were plotted throughout antibody treatment, fasting, and olive oil challenge.